• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊曲康唑联合棘白菌素类药物治疗唑类敏感和耐药的曲霉菌属

Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

机构信息

Hôpital Européen Georges Pompidou, APHP, Unité de Parasitologie-Mycologie, Service de Microbiologie, Paris, France.

Université Pierre et Marie Curie, Paris VI, Paris, France.

出版信息

Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01382-17. Print 2018 Jan.

DOI:10.1128/AAC.01382-17
PMID:29038263
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5740304/
Abstract

combinations of isavuconazole with echinocandins were evaluated against 30 strains with a two-dimensional checkerboard microdilution method and an agar-based diffusion method. With the checkerboard method, the three combinations showed indifferent interactions for all strains. With the agar-based method, indifferent interactions were found for all strains for isavuconazole-micafungin and isavuconazole-anidulafungin. For the isavuconazole-caspofungin combination, indifference was found in 24/30 strains, synergism in 4/30 strains, and antagonism in 2/30 strains.

摘要

采用二维棋盘微量稀释法和琼脂扩散法评估了伊曲康唑与棘白菌素类药物联合用药的效果,共评估了 30 株菌株。采用棋盘微量稀释法,三种联合用药对所有菌株均表现为无关作用。采用琼脂扩散法,伊曲康唑-米卡芬净和伊曲康唑-阿尼芬净对所有菌株均表现为无关作用。对于伊曲康唑-卡泊芬净的联合用药,在 30 株菌株中发现 24 株为无关作用,4 株为协同作用,2 株为拮抗作用。

相似文献

1
Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.伊曲康唑联合棘白菌素类药物治疗唑类敏感和耐药的曲霉菌属
Antimicrob Agents Chemother. 2017 Dec 21;62(1). doi: 10.1128/AAC.01382-17. Print 2018 Jan.
2
In vitro susceptibility of 188 clinical and environmental isolates of Aspergillus flavus for the new triazole isavuconazole and seven other antifungal drugs.188 株临床和环境黄曲霉分离株对新型三唑类药物伊曲康唑及其他七种抗真菌药物的体外药敏试验。
Mycoses. 2011 Sep;54(5):e583-9. doi: 10.1111/j.1439-0507.2010.01996.x. Epub 2011 Apr 25.
3
In vitro activity of isavuconazole against 208 Aspergillus flavus isolates in comparison with 7 other antifungal agents: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.体外异帕米星对 208 株黄曲霉与其他 7 种抗真菌药物的活性比较:根据欧洲抗菌药物敏感性测试委员会方法学进行评估。
Diagn Microbiol Infect Dis. 2011 Dec;71(4):370-7. doi: 10.1016/j.diagmicrobio.2011.08.006. Epub 2011 Sep 19.
4
Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018).长效棘白菌素类药物雷扎芬净与其他抗真菌药物对当代侵袭性真菌分离株的活性检测(SENTRY 项目,2016 年至 2018 年)。
Antimicrob Agents Chemother. 2020 Mar 24;64(4). doi: 10.1128/AAC.00099-20.
5
In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.体外伊曲康唑和阿尼芬净对唑类敏感性和唑类耐药烟曲霉分离株的相互作用。
J Antimicrob Chemother. 2020 Sep 1;75(9):2582-2586. doi: 10.1093/jac/dkaa185.
6
In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates.新型抗真菌化合物 F901318 对难治疗的曲霉属分离株的体外活性。
J Antimicrob Chemother. 2017 Sep 1;72(9):2548-2552. doi: 10.1093/jac/dkx177.
7
Comparative evaluation of different gradient diffusion tests for detection of azole resistance in Aspergillus fumigatus.不同梯度扩散试验用于检测烟曲霉唑类耐药性的比较评估
Diagn Microbiol Infect Dis. 2018 May;91(1):52-54. doi: 10.1016/j.diagmicrobio.2018.01.003. Epub 2018 Jan 9.
8
In vitro combination of isavuconazole with micafungin or amphotericin B deoxycholate against medically important molds.体外研究异氟康唑与米卡芬净或两性霉素B脱氧胆酸盐联合用于抗重要医学霉菌的效果。
Antimicrob Agents Chemother. 2014 Nov;58(11):6934-7. doi: 10.1128/AAC.03261-14. Epub 2014 Aug 18.
9
In vitro activity of isavuconazole versus opportunistic filamentous fungal pathogens from the SENTRY Antifungal Surveillance Program, 2017-2018.2017-2018 年 SENTRY 抗真菌监测计划中,伊曲康唑与机会性丝状真菌病原体的体外活性。
Diagn Microbiol Infect Dis. 2020 May;97(1):115007. doi: 10.1016/j.diagmicrobio.2020.115007. Epub 2020 Jan 29.
10
In vitro antifungal susceptibility of clinical and environmental isolates of Aspergillus fumigatus and Aspergillus flavus in Brazil.巴西烟曲霉和黄曲霉临床及环境分离株的体外抗真菌药敏性
Braz J Infect Dis. 2018 Jan-Feb;22(1):30-36. doi: 10.1016/j.bjid.2017.10.005. Epub 2017 Nov 22.

引用本文的文献

1
Aspergillosis: A comprehensive review of pathogenesis, drug resistance, and emerging therapeutics.曲霉病:发病机制、耐药性及新兴治疗方法的全面综述
J Food Drug Anal. 2025 Jun 13;33(2):75-96. doi: 10.38212/2224-6614.3547.
2
Antifungal Resistance in Non-fumigatus Aspergillus Species.非烟曲霉属真菌中的抗真菌耐药性
Mycoses. 2025 Apr;68(4):e70051. doi: 10.1111/myc.70051.
3
and evaluation of antifungal combinations against azole-resistant isolates.并评估抗真菌药物联合治疗对唑类耐药分离株的效果。
Front Cell Infect Microbiol. 2023 Jan 17;12:1038342. doi: 10.3389/fcimb.2022.1038342. eCollection 2022.
4
Antifungal Resistance and the Role of New Therapeutic Agents.抗真菌耐药性与新型治疗药物的作用
Curr Infect Dis Rep. 2022;24(9):105-116. doi: 10.1007/s11908-022-00782-5. Epub 2022 Jul 5.
5
Therapeutic innovation for multi-resistant candidemics: Synergy of isavuconazole and caspofungin association.多重耐药念珠菌血症的治疗创新:艾沙康唑与卡泊芬净联合用药的协同作用
Hematol Rep. 2021 Nov 26;13(4):9329. doi: 10.4081/hr.2021.9329.
6
In vitro and in vivo interaction of caspofungin with isavuconazole against Candida auris planktonic cells and biofilms.卡泊芬净与伊曲康唑对浮游细胞和生物膜的体外和体内相互作用对耳念珠菌的影响。
Med Mycol. 2021 Oct 4;59(10):1015-1023. doi: 10.1093/mmy/myab032.
7
Techniques for the Assessment of In Vitro and In Vivo Antifungal Combinations.体外和体内抗真菌联合用药评估技术
J Fungi (Basel). 2021 Feb 4;7(2):113. doi: 10.3390/jof7020113.
8
Antifungal Susceptibility Profiles and Drug Resistance Mechanisms of Clinical Lomentospora prolificans Isolates.临床多育卷枝毛霉分离株的抗真菌药敏谱及耐药机制
Antimicrob Agents Chemother. 2020 Oct 20;64(11). doi: 10.1128/AAC.00318-20.
9
Azole-resistant Aspergillus and Echinocandin-resistant Candida - What are the treatment options?耐唑类曲霉菌和耐棘白菌素念珠菌——治疗选择有哪些?
Curr Fungal Infect Rep. 2020 Jun;14(2):141-152. doi: 10.1007/s12281-020-00379-2. Epub 2020 Mar 26.
10
In vitro interaction of isavuconazole and anidulafungin against azole-susceptible and azole-resistant Aspergillus fumigatus isolates.体外伊曲康唑和阿尼芬净对唑类敏感性和唑类耐药烟曲霉分离株的相互作用。
J Antimicrob Chemother. 2020 Sep 1;75(9):2582-2586. doi: 10.1093/jac/dkaa185.

本文引用的文献

1
ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients.ECIL-6白血病和造血干细胞移植患者侵袭性念珠菌病、曲霉病和毛霉病治疗指南。
Haematologica. 2017 Mar;102(3):433-444. doi: 10.3324/haematol.2016.152900. Epub 2016 Dec 23.
2
Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.异曲康唑和米卡芬净单药或联合治疗小鼠毛霉菌病
J Antimicrob Chemother. 2017 Feb;72(2):462-466. doi: 10.1093/jac/dkw433. Epub 2016 Oct 24.
3
Spectrophotometric reading of EUCAST antifungal susceptibility testing of Aspergillus fumigatus.EUCAST 烟曲霉抗真菌药敏试验的分光光度读数。
Clin Microbiol Infect. 2017 Feb;23(2):98-103. doi: 10.1016/j.cmi.2016.10.017. Epub 2016 Oct 25.
4
Isavuconazole: A Review in Invasive Aspergillosis and Mucormycosis.伊曲康唑:在侵袭性曲霉病和毛霉病中的评价。
Drugs. 2016 Nov;76(17):1647-1657. doi: 10.1007/s40265-016-0652-6.
5
Synergistic effect of anidulafungin combined with posaconazole in experimental aspergillosis.阿尼芬净联合泊沙康唑在实验性曲霉病中的协同作用。
Med Mycol. 2017 Jun 1;55(4):457-460. doi: 10.1093/mmy/myw110.
6
Dose optimization of voriconazole/anidulafungin combination against Aspergillus fumigatus using an in vitro pharmacokinetic/pharmacodynamic model and response surface analysis: clinical implications for azole-resistant aspergillosis.使用体外药代动力学/药效学模型和响应面分析优化伏立康唑/阿尼芬净联合用药对烟曲霉的剂量:对唑类耐药曲霉病的临床意义
J Antimicrob Chemother. 2016 Nov;71(11):3135-3147. doi: 10.1093/jac/dkw276. Epub 2016 Jul 25.
7
Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America.曲霉病诊断和管理实践指南:美国感染病学会2016年更新版
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29.
8
Combinatorial strategies for combating invasive fungal infections.对抗侵袭性真菌感染的联合策略。
Virulence. 2017 Feb 17;8(2):169-185. doi: 10.1080/21505594.2016.1196300. Epub 2016 Jun 7.
9
Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial.伊曲康唑与伏立康唑治疗曲霉菌和其他丝状真菌所致侵袭性霉菌病的初步治疗(SECURE):一项 3 期随机对照非劣效性试验。
Lancet. 2016 Feb 20;387(10020):760-9. doi: 10.1016/S0140-6736(15)01159-9. Epub 2015 Dec 10.
10
International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.国际专家关于耐唑类烟曲霉感染管理的意见。
Drug Resist Updat. 2015 Jul-Aug;21-22:30-40. doi: 10.1016/j.drup.2015.08.001. Epub 2015 Aug 7.